PRTC
MCID: PRT010
MIFTS: 63

Parathyroid Carcinoma (PRTC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Parathyroid Carcinoma

Aliases & Descriptions for Parathyroid Carcinoma:

Name: Parathyroid Carcinoma 54 12 50 56 66 13 52 14
Parathyroid Cancer 50 29 52
Malignant Tumor of Parathyroid Gland 12 69
Parathyroid Gland Adenocarcinoma 12 69
Parathyroid Gland Neoplasm 12 29
Parathyroid Neoplasms 42 69
Malignant Neoplasm of Parathyroid Gland 12
Malignant Neoplasm of the Parathyroid 12
Carcinoma of Parathyroid Gland 12
Neoplasm of Parathyroid Gland 12
Parathyroid Gland Cancer 12
Parathyroid Neoplasm 12
Prtc 66

Characteristics:

Orphanet epidemiological data:

56
parathyroid carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adult; Age of death: adult,elderly;

HPO:

32
parathyroid carcinoma:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

OMIM 54 608266
Disease Ontology 12 DOID:1540
ICD10 33 C75.0
ICD9CM 35 194.1
MeSH 42 D010282
Orphanet 56 ORPHA143
ICD10 via Orphanet 34 C75.0
MedGen 40 C0687150

Summaries for Parathyroid Carcinoma

UniProtKB/Swiss-Prot : 66 Parathyroid carcinoma: These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.

MalaCards based summary : Parathyroid Carcinoma, also known as parathyroid cancer, is related to parathyroid cancer, childhood and cdc73-related parathyroid carcinoma, and has symptoms including constipation, fatigue and headache. An important gene associated with Parathyroid Carcinoma is CDC73 (Cell Division Cycle 73), and among its related pathways/superpathways are Hepatitis C and Hepatocellular Carcinoma and Transcription_Role of VDR in regulation of genes involved in osteoporosis. The drugs Sensipar and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, thyroid and lung, and related phenotypes are cardiovascular system and digestive/alimentary

Disease Ontology : 12 An endocrine gland cancer located in the parathyroid glands located in the neck.

Wikipedia : 71 Parathyroid carcinoma is a rare malignant neoplasm resulting in parathyroid adenoma to carcinoma... more...

Description from OMIM: 608266

Related Diseases for Parathyroid Carcinoma

Diseases in the Parathyroid Carcinoma family:

Cdc73-Related Parathyroid Carcinoma

Diseases related to Parathyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Related Disease Score Top Affiliating Genes
1 parathyroid cancer, childhood 11.9
2 cdc73-related parathyroid carcinoma 11.8
3 hyperparathyroidism-jaw tumor syndrome 11.2
4 hyperparathyroidism 10.4
5 deafness, autosomal recessive 42 10.2 CALCA CASR
6 stickler syndrome 10.2 CALCA PTH
7 adenoma 10.2
8 hypophosphatasia, adult 10.2 CALCA PTH
9 atrial heart septal defect 10.2 CALCA PTH
10 striatonigral degeneration 10.2 CASR PTH
11 acrorenal syndrome 10.2 CALCA PTH
12 axial osteomalacia 10.2 CALCA CDC73
13 gastric antral vascular ectasia 10.1 CASR PTH
14 restless legs syndrome 7 10.1 CDC73 MEN1
15 toenail dystrophy, isolated 10.1 CALCA PTH
16 ovarian endometrioid cystadenoma 10.1 CALCA PTH
17 parathyroid adenoma 10.1
18 pemphigus foliaceus 10.1 CALCA MEN1
19 paranasal sinus cancer, adult 10.1 CALCA MEN1
20 nodular prostate 10.1 CALCA LGALS3
21 hirschsprung disease 1 10.1 CALCA MEN1
22 gemistocytic astrocytoma 10.1 CALCA MEN1
23 weill-marchesani syndrome 10.1 CASR PTH
24 cowden syndrome 3 10.1 CALCA MEN1
25 macular holes 10.1 MEN1 PTH
26 cardioauditory syndrome of sanchez cascos 10.1 CALCA MEN1
27 keloids 10.1 CALCA MEN1
28 mediastinitis 10.1
29 strabismus 10.1 MEN1 PTH
30 caroli disease 10.1 CCND1 CDC73
31 familial chronic myelocytic leukemia-like syndrome 10.1 CASR CDC73 PTH
32 mesenchymal cell neoplasm 10.0 CALCA CASR PTH
33 cartilage disease 10.0 CALCA UCHL1
34 waardenburg syndrome, type 4b 10.0 CALCA CASR PTH
35 pes anserinus tendinitis or bursitis 10.0 CALCA CASR PTH
36 tinea unguium 10.0 CALCA CASR PTH
37 popliteal pterygium syndrome, bartsocas-papas type 10.0 CCND1 LGALS3
38 pre-eclampsia 10.0 CALCA CASR PTH
39 indian tick typhus 10.0 CALCA CASR PTH
40 aflatoxins-related hepatocellular carcinoma 10.0 CALCA PTH
41 peritoneal serous papillary adenocarcinoma 10.0 CALCA LGALS3
42 thyroiditis 10.0
43 aneurysm 10.0 CALCA MEN1
44 neuroretinitis 10.0 CCND1 MEN1
45 dysbaric osteonecrosis 10.0 CALCA PTH
46 immune system organ benign neoplasm 10.0 CDC73 MEN1 PTH
47 adult ependymoblastoma 10.0 CALCA MEN1 PTH
48 peritoneal mesothelioma 9.9 CALCA CCND1 LGALS3
49 benign shuddering attacks 9.9 CALCA LGALS3 MEN1
50 muscular dystrophy-dystroglycanopathy , type a, 10 9.9 CALCA LGALS3 MEN1

Comorbidity relations with Parathyroid Carcinoma via Phenotypic Disease Network (PDN):


Hyperparathyroidism

Graphical network of the top 20 diseases related to Parathyroid Carcinoma:



Diseases related to Parathyroid Carcinoma

Symptoms & Phenotypes for Parathyroid Carcinoma

Clinical features from OMIM:

608266

Human phenotypes related to Parathyroid Carcinoma:

56 32 (show all 38)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 constipation 56 32 Occasional (29-5%) HP:0002019
2 fatigue 56 32 Frequent (79-30%) HP:0012378
3 headache 56 32 Occasional (29-5%) HP:0002315
4 nausea and vomiting 56 32 Occasional (29-5%) HP:0002017
5 muscle weakness 56 32 Occasional (29-5%) HP:0001324
6 polydipsia 56 32 Frequent (79-30%) HP:0001959
7 bone pain 56 32 Occasional (29-5%) HP:0002653
8 dysphagia 56 32 Frequent (79-30%) HP:0002015
9 renal insufficiency 56 32 Occasional (29-5%) HP:0000083
10 hypophosphatemia 56 32 Very frequent (99-80%) HP:0002148
11 osteoporosis 56 32 Frequent (79-30%) HP:0000939
12 weight loss 56 32 Frequent (79-30%) HP:0001824
13 pancreatitis 56 32 Occasional (29-5%) HP:0001733
14 hypercalciuria 56 32 Very frequent (99-80%) HP:0002150
15 fibroma 56 32 Frequent (79-30%) HP:0010614
16 nephrocalcinosis 56 32 Frequent (79-30%) HP:0000121
17 nephrolithiasis 56 32 Frequent (79-30%) HP:0000787
18 hypercalcemia 56 32 Obligate (100%) HP:0003072
19 elevated circulating parathyroid hormone level 56 32 Very frequent (99-80%) HP:0003165
20 episodic abdominal pain 56 32 Occasional (29-5%) HP:0002574
21 peptic ulcer 56 32 Occasional (29-5%) HP:0004398
22 hoarse voice 56 32 Frequent (79-30%) HP:0001609
23 pancreatic adenocarcinoma 56 32 Very rare (<4-1%) HP:0006725
24 lipoma 56 32 Very rare (<4-1%) HP:0012032
25 testicular neoplasm 56 32 Very rare (<4-1%) HP:0010788
26 chondrocalcinosis 56 32 Occasional (29-5%) HP:0000934
27 nephroblastoma 56 32 Very rare (<4-1%) HP:0002667
28 thyroid carcinoma 56 32 Very rare (<4-1%) HP:0002890
29 renal cyst 56 32 Occasional (29-5%) HP:0000107
30 uterine leiomyoma 56 32 Frequent (79-30%) HP:0000131
31 parathyroid carcinoma 56 32 Obligate (100%) HP:0006780
32 infantile hypercalcemia 56 32 Frequent (79-30%) HP:0008250
33 primary hyperparathyroidism 56 32 Obligate (100%) HP:0008200
34 shortened qt interval 56 32 Frequent (79-30%) HP:0012232
35 renal hamartoma 56 32 Occasional (29-5%) HP:0008696
36 mandibular pain 56 32 Occasional (29-5%) HP:0200025
37 hyperparathyroidism 32 HP:0000843
38 abnormality of the parathyroid morphology 56 Very frequent (99-80%)

MGI Mouse Phenotypes related to Parathyroid Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.93 CCND1 CDC73 LGALS3 MEN1 PTH UCHL1
2 digestive/alimentary MP:0005381 9.91 CASR CCND1 CDC73 LGALS3 MEN1 UCHL1
3 homeostasis/metabolism MP:0005376 9.87 CASR CCND1 CDC73 LGALS3 MEN1 PTH
4 hematopoietic system MP:0005397 9.85 CASR CCND1 CDC73 LGALS3 PTH UCHL1
5 endocrine/exocrine gland MP:0005379 9.8 CASR CCND1 CDC73 MEN1 PTH
6 immune system MP:0005387 9.73 LGALS3 MEN1 PTH CASR CCND1 CDC73
7 integument MP:0010771 9.55 CASR CCND1 CDC73 LGALS3 UCHL1
8 mortality/aging MP:0010768 9.5 CASR CCND1 CDC73 LGALS3 MEN1 PTH
9 skeleton MP:0005390 9.02 CASR CCND1 LGALS3 PTH UCHL1

Drugs & Therapeutics for Parathyroid Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Sensipar 17 CINACALCET HYDROCHLORIDE Amgen Approved March 2004

Drugs for Parathyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
2
Zoledronic acid Approved Phase 4,Phase 3,Phase 1 118072-93-8 68740
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Glycerol Approved, Experimental Phase 4 56-81-5 753
5
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
6 tannic acid Approved, Nutraceutical Phase 4,Phase 2
7
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
8
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
9
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 32222-06-3 134070 5280453
10 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
13 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1
14 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1
15 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
19 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
20 vitamin d Phase 4,Phase 2,Phase 3,Phase 1
21 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
23 Diphosphonates Phase 4,Phase 3,Phase 2
24 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 1
25 Hydroxycholecalciferols Phase 4,Phase 3
26 Calcifediol Phase 4,Phase 3,Phase 1 19356-17-3
27 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
28 Hematinics Phase 4,Phase 2
29
s 1 (combination) Phase 4,Phase 2
30 Anti-Asthmatic Agents Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Betamethasone acetate Phase 4
33 Betamethasone benzoate Phase 4
34 Betamethasone sodium phosphate Phase 4
35 Betamethasone Valerate Phase 4 2152-44-5
36 Betamethasone-17,21-dipropionate Phase 4
37 glucocorticoids Phase 4
38 Respiratory System Agents Phase 4
39 Anticoagulants Phase 4
40 Chelating Agents Phase 4
41 Ferric Compounds Phase 4
42 Hepcidins Phase 4
43 Calciferol Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
44 Vitamin D2 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
45 Citrate Nutraceutical Phase 4
46
Citric Acid Nutraceutical, Vet_approved Phase 4 77-92-9 311
47 Olive Nutraceutical Phase 4
48
Calcium carbonate Approved Phase 3 471-34-1
49
Denosumab Approved Phase 3,Phase 2,Phase 1 615258-40-7
50 Gastrointestinal Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 182)
id Name Status NCT ID Phase
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4
2 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4
3 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4
4 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4
5 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4
6 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4
7 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4
8 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4
9 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4
10 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4
11 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4
12 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4
13 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4
14 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4
15 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4
16 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4
17 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4
18 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4
19 20070360 Incident Dialysis Completed NCT00803712 Phase 4
20 Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism Recruiting NCT02910466 Phase 4
21 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Recruiting NCT02652884 Phase 4
22 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Recruiting NCT02661295 Phase 4
23 Intravenous Paricalcitol in Chronic Hemodialysis Patients Active, not recruiting NCT03023748 Phase 4
24 Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients Active, not recruiting NCT02214563 Phase 4
25 Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT Not yet recruiting NCT03123406 Phase 4
26 Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects Terminated NCT00664430 Phase 4
27 Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis Terminated NCT00446329 Phase 4
28 Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) Unknown status NCT01479088 Phase 2, Phase 3
29 An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Completed NCT01460030 Phase 3
30 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
31 Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide Completed NCT01932970 Phase 3
32 The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss Completed NCT00375505 Phase 3
33 A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis Completed NCT00042653 Phase 3
34 Phase 3 Study of KHK7580 Completed NCT02549391 Phase 2, Phase 3
35 Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina Completed NCT00412087 Phase 3
36 Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism Completed NCT01341782 Phase 3
37 Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Completed NCT01704079 Phase 3
38 Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Completed NCT01651000 Phase 3
39 Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 Completed NCT02282813 Phase 3
40 Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet Completed NCT01896232 Phase 3
41 Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis Completed NCT01785849 Phase 3
42 Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Completed NCT01788046 Phase 3
43 Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis Completed NCT01785875 Phase 3
44 Calcium and Vitamin D Malnutrition in Elderly Women Completed NCT00352170 Phase 3
45 Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Completed NCT01219855 Phase 2, Phase 3
46 A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients Completed NCT00037635 Phase 3
47 Single-arm Extension Study on the Safety of Cinacalcet Treatment in SHPT in Pediatric Subjects With CKD on Dialysis Completed NCT02341417 Phase 3
48 SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00117052 Phase 3
49 The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS) Completed NCT02328404 Phase 3
50 Phase 3 Study of KHK7580 Recruiting NCT02549417 Phase 3

Search NIH Clinical Center for Parathyroid Carcinoma

Cochrane evidence based reviews: parathyroid neoplasms

Genetic Tests for Parathyroid Carcinoma

Genetic tests related to Parathyroid Carcinoma:

id Genetic test Affiliating Genes
1 Parathyroid Carcinoma 29
2 Neoplasm of the Parathyroid Gland 29

Anatomical Context for Parathyroid Carcinoma

MalaCards organs/tissues related to Parathyroid Carcinoma:

39
Bone, Thyroid, Lung, Lymph Node, Liver, Breast, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Parathyroid Carcinoma:

18
The Parathyroid Gl

Publications for Parathyroid Carcinoma

Articles related to Parathyroid Carcinoma:

(show top 50) (show all 519)
id Title Authors Year
1
Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. ( 28458892 )
2017
2
Giant parathyroid adenoma: differential aspects compared to parathyroid carcinoma. ( 28491324 )
2017
3
Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. ( 28011856 )
2017
4
Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. ( 28427885 )
2017
5
Denosumab as a long-term palliative therapy in parathyroid carcinoma. ( 28011854 )
2017
6
A nationwide study on parathyroid carcinoma. ( 28362521 )
2017
7
Spontaneous bilateral quadriceps tendon rupture revealing a parathyroid carcinoma. ( 28115266 )
2017
8
18F-FDG PET/CT Osteometabolic Activity in Metastatic Parathyroid Carcinoma. ( 27276208 )
2016
9
Multiple brown tumours from parathyroid carcinoma. ( 27358103 )
2016
10
Pathologic Fracture of the Femur in Brown Tumor Induced in Parathyroid Carcinoma: A Case Report. ( 27777921 )
2016
11
Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. ( 27609904 )
2016
12
Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. ( 27679651 )
2016
13
Oncologic progress for the treatment of parathyroid carcinoma is needed. ( 27753088 )
2016
14
Ossification of the cervical ligamentum flavum and osseous brown tumor: late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma. ( 27252748 )
2016
15
Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. ( 26939543 )
2016
16
A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature. ( 27544721 )
2016
17
Controversies in the management of parathyroid carcinoma: A case series and review of the literature. ( 26708847 )
2016
18
Parathyroid carcinoma in tertiary hyperparathyroidism. ( 27664600 )
2016
19
Parathyroid carcinoma presenting as mandibular ulceration. ( 26895764 )
2016
20
Is denosumab a long-term option for the treatment of parathyroid carcinoma? ( 26803154 )
2016
21
Somatic HRPT2 Mutation (Arg234X) of Parathyroid Carcinoma Associated with Slipped Capital Femoral Epiphysis: A First Case Report. ( 27266237 )
2016
22
Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?". ( 26803152 )
2016
23
Parathyroid carcinoma with contralateral subcutaneous and breast recurrences: A rare presentation. ( 26685878 )
2016
24
An unusual mediastinal parathyroid carcinoma coproducing PTH and PTHrP: A case report. ( 27313750 )
2016
25
Association of parathyroid carcinoma and thyroid disorders: A clinical review. ( 27744598 )
2016
26
A case of parathyroid carcinoma accompanied by a brown tumor. ( 27278852 )
2016
27
Difficult management in parathyroid carcinoma with synchronous parathyroid hyperplasia. ( 27677089 )
2016
28
Intrathyroidal parathyroid carcinoma. A case report and review of literature. ( 26588997 )
2016
29
Intrathyroidal oxyphilic parathyroid carcinoma: A potential diagnostic caveat in cytology? ( 27229757 )
2016
30
Parathyroid Carcinoma and Atypical Parathyroid Neoplasms in MEN1 Patients; A Clinico-Pathologic Challenge. The MD Anderson Case Series and Review of the Literature. ( 27212590 )
2016
31
Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. ( 27250989 )
2016
32
Parathyroid carcinoma. ( 26771263 )
2016
33
Update on parathyroid carcinoma. ( 27001435 )
2016
34
More Extensive Surgery May Not Improve Survival Over Parathyroidectomy Alone in Parathyroid Carcinoma. ( 27177488 )
2016
35
Parathyroid Carcinoma: Is It Time for Change? ( 26100817 )
2015
36
Parathyroid Carcinoma in a 10 Years Old Female Child. ( 26329966 )
2015
37
Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. ( 25387265 )
2015
38
Comment on: Is central lymph node dissection necessary for parathyroid carcinoma? ( 25921717 )
2015
39
Brain metastases of parathyroid carcinoma: Review of the literature and a case report. ( 25690525 )
2015
40
A Rare Constellation of HA1rthle Cell Thyroid Carcinoma and Parathyroid Carcinoma. ( 26813941 )
2015
41
Parathyroid carcinoma: A report of six cases with a brief review of the literature. ( 26788136 )
2015
42
Non-functional parathyroid carcinoma: a case report and review of the literature. ( 26408508 )
2015
43
Parathyroid carcinoma: Diagnostic criteria, classification, evaluation. ( 25916757 )
2015
44
Parathyroid Carcinoma: Diagnosis and Clinical Implications. ( 26177319 )
2015
45
Establishment and characterization of a human parathyroid carcinoma derived cell line. ( 25655355 )
2015
46
Is local resection sufficient for parathyroid carcinoma? ( 26017790 )
2015
47
Pulmonary Embolism and Subclavian Vein Thrombosis in a Patient with Parathyroid Carcinoma: Case Report and Review of Literature. ( 26591405 )
2015
48
Parathyroid carcinoma: Challenges in diagnosis and treatment. ( 25910997 )
2015
49
Clinicopathological phenotype of parathyroid carcinoma. Therapeutic and prognostic aftermaths. ( 25800319 )
2015
50
Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). ( 26077914 )
2015

Variations for Parathyroid Carcinoma

ClinVar genetic disease variations for Parathyroid Carcinoma:

6 (show all 16)
id Gene Variation Type Significance SNP ID Assembly Location
1 CDC73 NM_024529.4(CDC73): c.679_680insAG (p.Arg227Lysfs) insertion Pathogenic rs80356649 GRCh37 Chromosome 1, 193111146: 193111147
2 CDC73 NM_024529.4(CDC73): c.128G> A (p.Trp43Ter) single nucleotide variant Pathogenic rs121434263 GRCh37 Chromosome 1, 193091458: 193091458
3 CDC73 NM_024529.4(CDC73): c.162C> G (p.Tyr54Ter) single nucleotide variant Pathogenic rs121434265 GRCh37 Chromosome 1, 193094272: 193094272
4 CDC73 CDC73, 1-BP INS, 373A insertion Pathogenic
5 CDC73 CDC73, 4-BP DEL, 685AGAG deletion Pathogenic
6 CDC73 NM_024529.4(CDC73): c.85delG (p.Glu29Serfs) deletion Pathogenic rs587776560 GRCh37 Chromosome 1, 193091415: 193091415
7 CDC73 NM_024529.4(CDC73): c.13_30del18 (p.Leu5_Gln10del) deletion Pathogenic rs587776561 GRCh37 Chromosome 1, 193091343: 193091360
8 CDC73 NM_024529.4(CDC73): c.766_767delGT (p.Val256Lysfs) deletion Pathogenic rs80356650 GRCh37 Chromosome 1, 193117033: 193117034
9 CDC73 NM_024529.4(CDC73): c.687_688dupAG (p.Val230Glufs) duplication Pathogenic rs878855090 GRCh37 Chromosome 1, 193111154: 193111155
10 CDC73 NC_000001.11: g.(?_193130174)_(193130243_?)del deletion Pathogenic GRCh37 Chromosome 1, 193099304: 193099373
11 CDC73 NC_000001.11: g.(?_193203795)_(193236356_?)dup duplication Likely pathogenic GRCh38 Chromosome 1, 193203795: 193236356
12 CDC73 NM_024529.4(CDC73): c.245delA (p.Asn82Ilefs) deletion Pathogenic rs1060500009 GRCh38 Chromosome 1, 193130181: 193130181
13 CDC73 NM_024529.4(CDC73): c.4delG (p.Ala2Argfs) deletion Pathogenic rs1060500020 GRCh38 Chromosome 1, 193122204: 193122204
14 CDC73 NM_024529.4(CDC73): c.455_456delGA (p.Arg152Ilefs) deletion Pathogenic rs1060500019 GRCh38 Chromosome 1, 193138116: 193138117
15 CDC73 NM_024529.4(CDC73): c.729+1G> T single nucleotide variant Likely pathogenic rs1060500012 GRCh37 Chromosome 1, 193111197: 193111197
16 CDC73 NM_024529.4(CDC73): c.237+1G> C single nucleotide variant Pathogenic rs794727303 GRCh38 Chromosome 1, 193125218: 193125218

Expression for Parathyroid Carcinoma

Search GEO for disease gene expression data for Parathyroid Carcinoma.

Pathways for Parathyroid Carcinoma

Pathways related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.86 CCND1 UCHL1
2 10.61 CALCA PTH
3 10.21 CCND1 PTH

GO Terms for Parathyroid Carcinoma

Cellular components related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.13 CALCA CASR UCHL1
2 axon GO:0030424 8.8 CALCA CASR UCHL1

Biological processes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.67 CCND1 CDC73 MEN1 PTH
2 response to calcium ion GO:0051592 9.54 CASR CCND1
3 negative regulation of epithelial cell proliferation GO:0050680 9.52 CDC73 MEN1
4 cellular response to glucose stimulus GO:0071333 9.51 CASR MEN1
5 positive regulation of cAMP biosynthetic process GO:0030819 9.49 CALCA PTH
6 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.48 CALCA PTH
7 beta-catenin-TCF complex assembly GO:1904837 9.46 CDC73 MEN1
8 monocyte chemotaxis GO:0002548 9.43 CALCA LGALS3
9 response to ischemia GO:0002931 9.4 CASR UCHL1
10 vasodilation GO:0042311 9.32 CALCA CASR
11 positive regulation of calcium ion import GO:0090280 9.26 CASR LGALS3
12 positive regulation of ossification GO:0045778 9.16 CALCA PTH
13 cellular calcium ion homeostasis GO:0006874 9.13 CALCA CASR PTH
14 response to fibroblast growth factor GO:0071774 8.62 CASR PTH

Sources for Parathyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....